Revolution Medicines stock analysis
Want to see RVMD full AI Analyst Report?
Revolution Medicines (RVMD) Stock Price & Analysis
RVMD Stock Chart & Stats
- Day’s Range
- $168.62 - $176.06
- 52-Week Range
- $63.50 - $224.31
- Previous Close
- $176.35
- Volume
- N/A
- Average Volume (3M)
- 2.34M
- Market Cap
- $38.14B
- Enterprise Value
- $41.68B
- Total Cash (Recent Filing)
- $3.65B
- Total Debt (Recent Filing)
- $639.10M
- Price to Earnings (P/E)
- ―
- Beta
- 1.56
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- -1.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
FDA-approved Commercial Product
FDA approval converts RVMD from a development-stage biotechnology company into a commercial oncology business. Early product revenue, physician adoption, and patient uptake provide a durable foundation for future growth while validating the company’s ability to advance targeted therapies through late-stage development.
Broad Clinical Pipeline
The expanding Phase 3 portfolio creates multiple opportunities to extend the RAS(ON) platform beyond the initial pancreatic indication. Additional indications could diversify revenue, deepen the company’s oncology position, and increase the long-term value of its targeted drug-development capabilities.
Strong Capital Position
Substantial liquidity gives RVMD capacity to fund commercialization, clinical trials, and pipeline investment without immediately depending solely on equity markets. The retained financing flexibility also supports execution across several late-stage programs and improves resilience while revenue scales.
Bears Say
Severe Cash Burn
Very large negative operating and free cash flow means the current business is not yet self-funding despite the product launch. Continued investment across trials and commercialization could require substantial external capital, reducing financial flexibility if revenue growth or margins develop below expectations.
Deep And Widening Losses
Current revenue remains insufficient to absorb the cost of research, development, and commercial operations. Persistent and widening losses weaken earnings quality and increase the execution burden, requiring successful product expansion and disciplined spending before profitability can become durable.
Launch Economics Remain Uncertain
Initial sales benefited from expanded-access transitions and patients awaiting new treatment, so the eventual recurring demand profile is not yet established. Shorter treatment durations, evolving payer policies, and higher discounts could make future net revenue less predictable than early results suggest.
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
What is Revolution Medicines’s market cap?
When is Revolution Medicines’s upcoming earnings report date?
How were Revolution Medicines’s earnings last quarter?
Is Revolution Medicines overvalued?
Does Revolution Medicines pay dividends?
What is Revolution Medicines’s EPS estimate?
How many shares outstanding does Revolution Medicines have?
What happened to Revolution Medicines’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Revolution Medicines?
What is the TipRanks Smart Score and how is it calculated?
Revolution Medicines Stock Smart Score
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Website
- www.revmed.com
- Address
- 700 Saginaw Drive, Redwood City, CA, 94063, US
Revolution Medicines (RVMD) Earnings & Revenues
RVMD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by FDA approval, a rapid initial U.S. launch generating $198 million in revenue from more than 5 thousand commercial patients, broad early physician and payer access, positive regulatory progress in Europe, and continued advancement across pancreatic, lung, colorectal, and earlier-stage RAS(ON) programs. The principal challenges were that launch revenue includes finite early cohorts, normalized demand remains uncertain, formal payer policies are still developing, European approval is pending, and expenses and net loss increased substantially. Overall, the number and significance of the achievements materially outweighed the stated challenges.
View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 2 | 12 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 2 | 0 | 10 |
